Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,376.00GBp
5:25pm IST
Change (% chg)

-22.00 (-0.41%)
Prev Close
5,398.00
Open
5,399.00
Day's High
5,405.00
Day's Low
5,360.00
Volume
397,102
Avg. Vol
2,014,212
52-wk High
5,585.07
52-wk Low
4,260.00

Latest Key Developments (Source: Significant Developments)

Astrazeneca Says Lokelma Approved In U.S. For The Treatment Of Adults With Hyperkalaemia
Monday, 21 May 2018 

May 21 (Reuters) - AstraZeneca PLC ::LOKELMA PROVIDES RAPID AND SUSTAINED POTASSIUM CONTROL FOR PATIENTS IN A CONDITION WITH HIGH UNMET NEED.US FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED LOKELMA (SODIUM ZIRCONIUM CYCLOSILICATE), FORMERLY ZS-9, FOR TREATMENT OF ADULTS WITH HYPERKALAEMIA,1.  Full Article

Astrazeneca CEO Says In Ongoing Discussions With Investors On Bonuses
Friday, 18 May 2018 

May 18 (Reuters) - AstraZeneca PLC CEO Pascal Soriot tells reporters::CEO SAYS IN ONGOING DISCUSSIONS WITH INVESTORS TO ADDRESS CONCERNS ON EXECUTIVE BONUS SCHEME.  Full Article

AstraZeneca Says Galathea Phase III Trial Did Not Meet Primary Endpoint
Friday, 11 May 2018 

May 11 (Reuters) - AstraZeneca PLC ::ASTRAZENECA UPDATE ON FASENRA PIII TRIAL IN COPD.GALATHEA PHASE III TRIAL DID NOT MEET PRIMARY ENDPOINT OF A STATISTICALLY-SIGNIFICANT REDUCTION OF EXACERBATIONS IN PATIENTS WITH COPD.SECOND PHASE III TRIAL TERRANOVA IS ONGOING WITH RESULTS EXPECTED LATER THIS QUARTER.SAFETY AND TOLERABILITY FINDINGS IN GALATHEA WERE CONSISTENT WITH THOSE OBSERVED IN PREVIOUS TRIALS WITH FASENRA.RESULTS OF GALATHEA TRIAL DO NOT IMPACT APPROVED INDICATION IN SEVERE EOSINOPHILIC ASTHMA.GALATHEA PHASE III TRIAL DID NOT MEET PRIMARY ENDPOINT OF A STATISTICALLY-SIGNIFICANT REDUCTION OF EXACERBATIONS IN PATIENTS WITH COPD.  Full Article

AstraZeneca Says Lynparza Tablets Receive EU Approval
Tuesday, 8 May 2018 

May 8 (Reuters) - AstraZeneca PLC ::EMA APPROVES LYNPARZA: MAINTENANCE OVARIAN CANCER.LYNPARZA TABLETS RECEIVE EU APPROVAL FOR TREATMENT OF PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER.  Full Article

Luye Pharma Group Acquires Astrazeneca's Rights Relating To Seroquel And Seroquel XR
Monday, 7 May 2018 

May 7 (Reuters) - Luye Pharma Group Ltd <2186.HK>::ANNOUNCES ACQUISITION OF ASTRAZENECA'S RIGHTS RELATING TO SEROQUEL AND SEROQUEL XR IN CHINA AND IN OTHER TERRITORIES.PURCHASE PRICE FOR TRANSFERRED ASSETS AND LICENSED ASSETS IS IN AGGREGATE SUM OF US$546 MILLION.ASTRAZENECA TO TRANSFER ASSETS & GRANT A LICENCE FOR ASSETS TO UNIT IN TERRITORIES INCLUDING CHINA, BRAZIL, AMONG OTHERS.  Full Article

Redx Pharma Appoints Astrazeneca Executive Lisa Anson As CEO
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Redx Pharma PLC ::REDX PHARMA PLC - REDX APPOINTS SENIOR ASTRAZENECA EXECUTIVE AS CEO.REDX PHARMA PLC - APPOINTED LISA ANSON AS CHIEF EXECUTIVE OFFICER (CEO) AND TO ITS BOARD OF DIRECTORS.  Full Article

Ionis And AstraZeneca Advance New Drug For NASH
Monday, 9 Apr 2018 

April 9 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS AND ASTRAZENECA ADVANCE NEW DRUG FOR NASH.IONIS PHARMACEUTICALS INC - EARNS $30 MLN LICENSE FEE FOR IONIS-AZ6-2.5-L RX.IONIS PHARMACEUTICALS INC - ASTRAZENECA WILL BE RESPONSIBLE FOR FURTHER DEVELOPMENT & COMMERCIALIZATION OF IONIS-AZ6-2.5-LRX.IONIS PHARMACEUTICALS INC - AS IONIS-AZ6-2.5-LRX ADVANCES, CO MAY RECEIVE UP TO $300 MLN IN ADDITIONAL DEVELOPMENT & REGULATORY MILESTONE PAYMENTS.  Full Article

Astrazeneca Announces Renewed U.S. Recommendation, Availability Of Flumist Quadrivalent Vaccine
Thursday, 22 Feb 2018 

Feb 21 (Reuters) - AstraZeneca PLC ::ASTRAZENECA ANNOUNCES RENEWED RECOMMENDATION AND AVAILABILITY OF FLUMIST QUADRIVALENT VACCINE IN THE US.ASTRAZENECA - RESULTS DEMONSTRATED NEW 2017-2018 H1N1 LAIV POST-PANDEMIC STRAIN PERFORMED BETTER THAN 2015-2016 H1N1 LAIV POST-PANDEMIC STRAIN​.ASTRAZENECA - CDC'S ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES VOTED IN FAVOR OF RENEWED RECOMMENDATION FOR FLUMIST QUADRIVALENT USE IN U.S. 2018-2019 SEASON.  Full Article

Astrazeneca Says ‍Fasenra Receives EU Approval
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Astrazeneca Plc ::‍FASENRA RECEIVES EU APPROVAL FOR SEVERE EOSINOPHILIC ASTHMA​.ASTRAZENECA - ‍FASENRA IS ALSO UNDER REGULATORY REVIEW IN JAPAN AND SEVERAL OTHER COUNTRIES, WITH EXPECTED REGULATORY DECISIONS IN H1 2018​.  Full Article

Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Myriad Genetics Inc ::MYRIAD GENETICS ANNOUNCES EXPANDED RESEARCH COLLABORATION WITH ASTRAZENECA.MYRIAD GENETICS INC - FINANCIAL TERMS WERE NOT DISCLOSED..MYRIAD GENETICS INC - UNDER AGREEMENT, MYRIAD WILL USE ITS MYCHOICE HRD PLUS TEST TO EVALUATE PATIENTS ENROLLED IN AN ONGOING PHASE III TRIAL.  Full Article

Lilly-AstraZeneca latest to abandon Alzheimer's drug trials

Eli Lilly and Co and AstraZeneca Plc said on Tuesday they would discontinue late-stage trials testing their Alzheimer's treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.